Figure 12.
Sox9 expression in BECs is maintained by Yap. (A) Verteporfin treatment does not impact organoid morphology (scale bar = 50 μm) but (B) results in significant down-regulation of Sox9 and established BEC Yap targets, Cyr61 and Klf6, whereas Gadd45b is unaffected (∗ indicates significance, P < .05; ∗∗ indicates significance, P ≤ .01, unpaired t test).